Treprostinil Palmitil Inhalation Powder

Phase 3

Insmed Incorporated (INSM)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Past

days

INSMPhase 3$11.0B

✓Positive

Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected

Treprostinil Palmitil Inhalation Powder• Pulmonary Hypertension31

Mar 14Estimated

CT.gov

Competitive Landscape

3 competitors in Pulmonary Hypertension

TENXTNX-103

Phase 3

View Full Landscape

Drug Information

Target Indication

Pulmonary Hypertension

Clinical Trial

NCT05649722

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Treprostinil SciPharm Sàrl

Treatment of chronic thromboembolic pulmonary hypertension

View on EMA

EMA4/3/2020

Trepulmix

Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

INSM

Insmed Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3

Pseudomonas Aeruginosa Infection

LAI 590 mgPhase 3

NTM Lung Infection Due to MAC

Liposomal amikacin for inhalationPhase 3

Cystic Fibrosis

Brensocatib 25 mgPhase 3

Non-Cystic Fibrosis Bronchiectasis

Treprostinil PalmitilPhase 3

Pulmonary Hypertension

View full pipeline